Current status of ARBs in BD.ppt

3,788 views

Published on

Published in: Sports, Technology
1 Comment
8 Likes
Statistics
Notes
  • mama, valoi to dila.........
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
3,788
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
5
Comments
1
Likes
8
Embeds 0
No embeds

No notes for slide

Current status of ARBs in BD.ppt

  1. 1. ARBs (Angiotensin II Receptor Blockers) Presented by Mohammed Moshiur Rahaman Brand Executive Brand Management Department Strategic Brand Management Division The ACME Laboratories Ltd.
  2. 2. Indications  Main Indication : For the treatment of hypertension  Other Indications : 1. Diabetic nephropathy (kidney damage due to diabetes) 2. Congestive heart failure
  3. 3. Available ARBs In World  Losartan  Candesartan  Valsartan  Irbesartan  Telmesartan  Eprosartan  Olmesartan (FDA 2002)  Azilsartan (FDA 2011)
  4. 4. Available ARBs In Bangladesh (3Q, 2012) Generic Introduce (Year) Market (Crore) Growth Losartan 2001 91.99 33.29 Valsartan 2003 10.16 0.53 Olmesartan 2010 8.45 81.11 Irbesartan 2002 2.96 49.56 Telmesartan 2005 0.77 -24.88 Candesarta n 2003 0.37 -30.76
  5. 5. Azilsartan Olmesartan Valsatan Losartan Generic Azilsartan Medoxomil INN Olmesartan Medoxomil USP Valsartan INN Losartan Potassium USP Therapeutic Class Antihypertensive (ARBs) Antihypertensive (ARBs) Antihypertensive (ARBs) Antihypertensive (ARBs) Dosage Form Tablet Tablet Tablet Tablet Strength 40 mg & 80 mg 10 mg, 20 mg & 40 mg 40 mg, 80 mg & 160 mg 25 mg, 50 mg & 100 mg Drug Interactions No significant drug-drug interactions No significant drug-drug interactions No significant drug-drug interactions No significant drug-drug interactions Pregnancy category D C C C Use in children Safety and effectiveness have not been established Safety and effectiveness have been established Safety and effectiveness have not been established Safety and effectiveness have been established FDA/BNF approval FDA approved (2011) FDA approved (2002) FDA approved (2001) FDA approved (1995) Pharmacokinetic data Bioavailability: 60% Half-life: 11 hours Bioavailability: 29% Half-life: 13 hours Bioavailability: 25% Half-life: 6 hours Bioavailability: 33% Half-life: 6-9 hours AT1 affinity More than 10000 fold 12500 fold 20000 fold 10000 fold tmax (h) 1.5-3.0 hrs 1.4-2.8 hrs 2 hrs 3-4 hrs
  6. 6. Clinical Trails Azilsartan at its maximal dose has superior efficacy to both Olmesartan and Valsartan at their maximal, approved doses without increasing adverse events. Azilsartan could provide higher rates of hypertension controls within the ARB class. Ref: Hypertension, 2011 Mar, 57 (3): 413-420. Epub 2011 Jan 31 (Pubmed)
  7. 7. Price Comparison Angiotensin II Receptor Antagonist Price/Dose Price/Month Annual Price/Patient Azilsartan 40 mg tablet $0.735 $22.05 $264.60 80 mg tablet $0.735 $22.05 $264.60 25 mg tablet $0.291 $8.73 $104.76 50 mg tablet $0.0746 $2.238 $26.86 100 mg tablet $0.1015 $3.045 $36.54 5 mg tablet $1.0273 $30.819 $369.83 20 mg tablet $1.1029 $33.087 $397.04 40 mg tablet $1.1683 $35.049 $420.59 40 mg tablet $0.3003 $9.009 $108.11 80 mg tablet $0.3000 $9.00 $108.00 160 mg tablet $0.3000 $9.00 $108.00 320 mg tablet $0.6502 $19.506 $234.07 Losartan Olmesartan Valsartan

×